This phase III trial is comparing the safety and effectiveness of a targeted therapy and standard chemotherapy for the treatment of patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer.
This trial is treating patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Commercial Sponsor
ImmunoGen, Inc.
Summary
Eligible patients will be randomised to receive mirvetuximab soravtansine (MIRV) or the investigator's choice of chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).
Recruiting Hospitals Read More